Media release
From: JAMAPaper 1
Examining Association Between Early Treatment WithTocilizumab, Risk of Death Among Critically Ill COVID-19Patients
What The Study Did:
Whether treatment with tocilizumab in the first two days after being admitted to an intensivecare unit was associated with a reduced risk of death among critically ill patients with COVID-19 was investigated inthis study.
Authors: David E. Leaf, M.D., M.M.Sc., of Brigham and Women’s Hospital in Boston, is the corresponding author.
Paper 2
Tocilizumab vs Standard Care on Preventing Worsening inPatients Hospitalized With COVID-19 Pneumonia
What The Study Did:
Researchers in this randomized clinical trial compared the effect of early administration oftocilizumab with standard therapy in preventing clinical worsening in patients hospitalized with COVID-19pneumonia.
Authors: Carlo Salvarani, M.D., of Unita Operativa di Reumatologia in Reggio Emilia, Italy, is the corresponding author.
Paper 3
Effect of Tocilizumab in Adults Hospitalized With COVID-19With Moderate or Severe Pneumonia
What The Study Did:
This randomized clinical trial assessed whether tocilizumab improves outcomes of patientshospitalized with moderate-to-severe COVID-19 pneumonia compared to usual care.
Authors: Olivier Hermine, M.D., Ph.D., of the Université de Paris, is the corresponding author.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.